Endo’s Bivalirudin Injection in Ready-to-Use Vials Launched in United States

July 18, 2023—Endo International plc, an Ireland-based specialty pharmaceutical company, announced that its Par Sterile Products business has begun shipping bivalirudin injection in a 250-mg/50-mL single-use vial in the United States.

As stated in the company’s press release, the ready-to-use liquid format of bivalirudin does not require reconstitution, dilution, or mixing. Bivalirudin injection is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention, including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. It is manufactured by Gland Pharma Limited, India.

In May 2023, Endo executed agreements with Maia Pharmaceuticals, Inc. and Gland Pharma Limited to commercialize ready-to-use bivalirudin in the United States, noted the company.